SCHEMBL1963502

SCHEMBL1963502

CC(C)Oc1ncc(C(N)=O)cc1Cl

nearest known ligand 0.44

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PARP10 Q53GL7 1/20 0.44
S1PR1 P21453 7/20 0.42
S1PR5 Q9H228 2/20 0.42
S1PR3 Q99500 1/20 0.42
TYK2 P29597 1/20 0.42
RORC P51449 1/20 0.41
LMNA P02545 1/20 0.40
HTT P42858 1/20 0.40
HPGDS O60760 1/20 0.38
SCN9A Q15858 2/20 0.38
NNMT P40261 1/20 0.38
CNR1 P21554 1/20 0.38
ACACB O00763 1/20 0.37
RPS6KB1 P23443 1/20 0.37
MKNK1 Q9BUB5 1/20 0.36
MKNK2 Q9HBH9 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL404384 0.86 RORC (0.45) S1PR1S1PR5S1PR3RORCSCN9A
SCHEMBL1013088 0.86 RORC (0.42) S1PR1S1PR5S1PR3RORCSCN9A
SCHEMBL3957207 0.84 S1PR1 (0.41) S1PR1S1PR5S1PR3RORCSCN9A
SCHEMBL1964065 0.83 RORC (0.43) S1PR1S1PR5S1PR3RORCLMNA
SCHEMBL401766 0.83 P2RY12 (0.45) S1PR1S1PR5S1PR3RORCSCN9A
Hydrochloric Acid SCHEMBL27669705 0.82 S1PR1 (0.41) S1PR1S1PR5S1PR3RORCSCN9A
SCHEMBL17627108 0.82 RORC (0.41) S1PR1S1PR5S1PR3RORCSCN9A
SCHEMBL1965618 0.82 S1PR1 (0.37) S1PR1S1PR5S1PR3TYK2RORC
SCHEMBL1965620 0.82 S1PR1 (0.37) S1PR1S1PR5S1PR3TYK2RORC
SCHEMBL3950931 0.82 S1PR1 (0.42) S1PR1S1PR5S1PR3RORCSCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116836157-A Oxadiazole derivative and preparation method and application thereof 星希尔生物科技(上海)有限公司 2023-10-03 CN disclosed
WO-2023179366-A1 OXADIAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF 星希尔生物科技(上海)有限公司 2023-09-28 WO disclosed
EP-2509424-A1 NOVEL OXADIAZOLE COMPOUNDS Abbott Laboratories (US) 2012-10-17 EP disclosed
US-20110207704-A1 Novel Oxadiazole Compounds ABBOTT LABORATORIES (US) 2011-08-25 US disclosed
US-20110207704-A1 Novel Oxadiazole Compounds ABBOTT LABORATORIES (US) 2011-08-25 US disclosed
US-20110207704-A1 Novel Oxadiazole Compounds ABBOTT LABORATORIES (US) 2011-08-25 US disclosed
WO-2011071570-A1 NOVEL OXADIAZOLE COMPOUNDS ABBOTT LABORATORIES (US) 2011-06-16 WO disclosed
WO-2011071570-A1 NOVEL OXADIAZOLE COMPOUNDS ABBOTT LABORATORIES (US) 2011-06-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110207704-A1 Novel Oxadiazole Compounds S1PR3, S1PR1, S1PR2 PARP10 2128/4885S1PR1 2/4885S1PR5 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.